As most studies have been conducted in postmenopausal women, the American Society of Clinical Oncology (ASCO) guidelines currently recommend the use of EndoPredict to guide treatment decision only in postmenopausal women with node-negative or node-positive with 1–3 positive nodes, hormone receptor-positive HER2-negative early breast cancer [2]. This evidence concerns the gene ERBB2 and breast carcinoma.